The retina is, gram for gram, one of the most metabolically demanding tissues in the human body. It consumes oxygen at a rate approaching that of heart muscle — and unlike the heart, it has very limited reserve capacity. When oxygen delivery to retinal tissue is reduced, even briefly and repeatedly, the consequences accumulate in ways that manifest as the progressive vision loss of diabetic retinopathy. For a diabetic smoker, two powerful sources of retinal oxygen deprivation are operating simultaneously: the microvascular disease driven by chronic hyperglycaemia, and the carbon monoxide and vasoconstriction driven by cigarette smoke.
Smoking worsens diabetic retinopathy through three mechanisms: CO-mediated retinal tissue hypoxia (carbon monoxide reduces oxygen delivery to the retina's already-compromised microvasculature); oxidative damage from reactive oxygen species that directly damage retinal pigment epithelium and photoreceptors; and disruption of the VEGF pathway that drives abnormal new vessel formation (neovascularisation) — the defining feature of proliferative diabetic retinopathy, which carries the highest risk of severe vision loss. A study from Cell and Molecular Biology (Abubakar et al.) and data from the Beichen Eye Study both confirm smoking as an independent risk factor for diabetic retinopathy progression and retinal neurodegeneration in T2DM patients.
How the Diabetic Retina Is Already Vulnerable
Diabetic retinopathy begins with damage to the retinal microvasculature — the network of tiny capillaries that supply the photoreceptors and other retinal cells with oxygen and glucose. Chronic hyperglycaemia damages these vessels through AGE formation, oxidative stress, and pericyte loss (pericytes are the cells that support and stabilise capillary walls). As the capillary walls weaken, they become leaky — allowing fluid to accumulate in the retina (macular oedema) — or occluded — creating zones of retinal ischaemia (areas deprived of blood supply). In response to ischaemia, the retina releases VEGF (vascular endothelial growth factor) to stimulate new blood vessel growth. These new vessels, however, are fragile and poorly formed — they bleed easily into the vitreous (the jelly-like interior of the eye), causing vision loss from proliferative retinopathy.
The Three Mechanisms: How Smoking Compounds Retinal Damage
Carbon monoxide from cigarette smoke reduces the oxygen-carrying capacity of haemoglobin and shifts the oxygen dissociation curve leftward — reducing oxygen delivery to all tissues, including the retina. The retina, with its extremely high metabolic demands and limited vascular reserve, is among the most sensitive tissues to oxygen deprivation. CO-induced retinal hypoxia directly stimulates VEGF production — promoting exactly the abnormal neovascularisation that defines proliferative retinopathy. In a diabetic patient whose retinal capillaries are already partially occluded and whose retinal oxygenation is already reduced, CO adds a further hypoxic burden that accelerates the ischaemic signal driving neovascularisation.
Cigarette smoke is a potent source of reactive oxygen species (ROS) that cause oxidative damage to lipids, proteins, and DNA. The retina is particularly vulnerable to oxidative damage because: it has very high metabolic activity (generating endogenous ROS as a byproduct of photoreceptor function); it contains high concentrations of polyunsaturated fatty acids in photoreceptor membranes (which are susceptible to lipid peroxidation); and it has relatively limited antioxidant defences. Chronic smoke-derived ROS exposure damages retinal pigment epithelium (RPE), photoreceptors, and ganglion cells — contributing to the retinal neurodegeneration that the Beichen Eye Study confirmed as independently associated with T2DM. The combination of hyperglycaemia-driven ROS (from AGE formation, NADPH oxidase activation) and smoke-derived ROS produces additive oxidative damage to retinal tissue.
VEGF (vascular endothelial growth factor) is the primary driver of the abnormal new blood vessel formation in proliferative diabetic retinopathy. Both diabetes and smoking independently elevate VEGF expression in retinal tissue — diabetes through ischaemia-driven upregulation, smoking through CO-mediated hypoxia, oxidative stress, and direct nicotinic receptor activation. When both stimuli are present simultaneously, VEGF production is elevated by two independent pathways, and the drive toward neovascularisation is greater than either condition alone would produce. This explains why diabetic smokers may progress from non-proliferative to proliferative retinopathy faster than non-smoking diabetics with comparable HbA1c and diabetes duration. Research from Cell and Molecular Biology (Abubakar et al.) confirmed the specific role of smoking and environmental toxins in accelerating diabetic retinopathy through oxidative and VEGF mechanisms.
The Stages of Diabetic Retinopathy — and What Smoking Does at Each
Normal fundus
Microaneurysms only
Intraretinal changes
Neovascularisation
The AMD Connection — Diabetics Who Smoke Face Two Eye Risks
Smoking is the strongest modifiable risk factor for age-related macular degeneration (AMD) — a separate condition from diabetic retinopathy that affects central vision. Smokers have 2–4 times higher risk of AMD than non-smokers. Diabetics already carry elevated AMD risk due to shared oxidative stress and vascular pathology. A diabetic smoker therefore carries simultaneously elevated risk for both diabetic retinopathy (from hyperglycaemia + smoking) and AMD (from smoking). The two conditions can coexist in the same patient and both affect the macula — the central zone of the retina responsible for fine vision, reading, and face recognition.
Every person with diabetes should have annual dilated fundus examination (retinal photography or ophthalmoscopy) — regardless of whether they have symptoms. Early diabetic retinopathy has no symptoms. By the time vision changes are noticeable, significant irreversible damage has usually already occurred.
If you smoke and have diabetes, annual eye examination is not optional — it is a clinical priority. If you have not had a retinal examination in the past 12 months, book one now. Most ophthalmology departments in government hospitals offer retinal screening; fundus photography is available at most diagnostic centres in Indian cities.
Cessation and retinopathy treatment: Anti-VEGF injections (ranibizumab, bevacizumab, aflibercept) are the primary treatment for proliferative diabetic retinopathy and diabetic macular oedema. These agents work by blocking VEGF. If you smoke while receiving anti-VEGF treatment, smoking is continuously driving VEGF production through CO-induced ischaemia and oxidative stress — working against the medication. Cessation improves the therapeutic environment for retinopathy treatment.
For diabetic smokers with retinopathy who are working toward cessation, reducing the oxidative compound load in each cigarette directly reduces the ROS burden on retinal tissue. Smokesafer Gold's 68% acrolein reduction, 67% formaldehyde reduction, and 79% acetaldehyde reduction address the primary reactive carbonyl species responsible for retinal oxidative damage. The 71% CO reduction directly addresses the hypoxia-VEGF mechanism. These are the most retina-relevant compound reductions in the lab data. See the lab data →
Frequently Asked Questions
The Bottom Line
Diabetic retinopathy is already driven by the microvascular damage of chronic hyperglycaemia. Smoking adds three simultaneous mechanisms that accelerate this progression: CO-mediated retinal ischaemia that drives VEGF production, oxidative damage from reactive smoke compounds that directly harms retinal cells, and VEGF pathway disruption that promotes the abnormal neovascularisation of proliferative disease. Annual retinal examination is non-negotiable for diabetic smokers. Cessation improves both the underlying retinal environment and the effectiveness of retinopathy treatments.